The BID Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the human BID gene, encoding the BH3-interacting domain death agonist. This loss-of-function model is designed for investigating the molecular mechanisms of apoptosis signaling, particularly the cross-talk between extrinsic death receptor pathways and the intrinsic mitochondrial apoptotic cascade. The polyclonal knockout pool preserves population-level heterogeneity, enabling robust functional genomics studies without the clonal selection artifacts that can arise from single-cell-derived lines.
The host cell model, HAP1, is a near-haploid human cell line derived from the KBM-7 chronic myeloid leukemia background. Its haploid karyotype simplifies genetic manipulation and phenotype-genotype correlation, making it a powerful platform for functional genomics studies of human myeloid leukemia biology. HAP1 cells retain key characteristics of myeloid lineage, including sensitivity to apoptotic stimuli relevant to cancer and hematopoietic malignancies. This host enables precise dissection of gene function within a disease-relevant cellular context.
BID functions as a critical pro-apoptotic BH3-only protein that links death receptor signaling to mitochondrial outer membrane permeabilization. Upon activation by death receptor ligands such as FasL, TRAIL, or TNF-??, BID is proteolytically cleaved by caspase-8 to generate truncated BID (tBID). tBID subsequently translocates to mitochondria, where it interacts with and activates multi-domain pro-apoptotic effectors BAX and BAK, promoting their oligomerization and mitochondrial pore formation. This event triggers cytochrome c release and activation of the apoptosome, leading to caspase-9 and caspase-3 cleavage. BID activity is modulated by upstream regulators including ATM, p53, and granzyme B, and is antagonized by anti-apoptotic Bcl-2 family members such as Bcl-2, Bcl-xL, and Mcl-1, which bind and neutralize its function.
In the HAP1 myeloid leukemia background, knockout of BID disrupts the intrinsic apoptosis execution arm downstream of death receptors and DNA damage signaling. This model is particularly valuable for deconvoluting apoptotic signaling in chronic myeloid leukemia, where dysregulation of Bcl-2 family proteins often contributes to drug resistance and leukemic cell survival. BID-deficient HAP1 cells provide a clean genetic system to evaluate the specificity of BH3-mimetic drugs, study compensatory survival pathways activated upon loss of mitochondrial apoptosis, and interrogate caspase-8-independent functions of BID in non-apoptotic processes such as mitochondrial dynamics or innate immunity.
The BID Knockout HAP1 Polyclonal Cells enable a broad range of apoptosis-focused research applications. They serve as a reliable tool for western blotting analysis of cytochrome c release and caspase processing, flow cytometric quantification of cell death kinetics following extrinsic or intrinsic apoptotic triggers, and mitochondrial fractionation assays to validate tBID translocation. Researchers can also employ BH3 profiling to assess mitochondrial priming in the absence of BID, perform co-immunoprecipitation studies to map BID interactions with BAX or anti-apoptotic partners, and use immunofluorescence to visualize tBID localization. These applications are particularly relevant for preclinical evaluation of next-generation BH3-mimetics, studies of therapy-induced senescence evasion, and functional genomics screens in DNA damage response pathways. For additional information or technical support, please contact Ascent Research.
